Farletuzumab (MORAb-003) is a humanized monoclonal antibody with a high affinity for folate receptor-α (FRα), acting as a potent inhibitor of FRα and impeding the growth of cells that overexpress this receptor, making it useful for cancer research.

In CHO-FR cells, Farletuzumab (MORAb-003; 0-10 µg/mL) inhibits FRα-dependent cell growth and increases folate EC50 in a dose-dependent manner[1].
In IGROV-1 cells (0.1-100 µg/mL; 1 h), Farletuzumab mediates tumor cytotoxicity in vitro through complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC)[1].
In CHO-FR cells (0-10 µg/mL), Farletuzumab inhibits the phosphorylation of proteins by Lyn kinase, a member of the src family of kinases, thereby blocking an FRα-mediated signaling pathway[1].